Company: LCTX
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0000950170-25-070378
Chunk: 1

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 1
Chunk 1
---
ments and contingencies (Note 13)

     SHAREHOLDERS’ EQUITY

     Preferred shares, no par value, 2,000 shares authorized; none issued and    outstanding as of March 31, 2025 and December 31, 2024

     —

     —

     Common shares, no par value, 450,000 shares authorized as of    March 31, 2025 and December 31, 2024; 228,356 and 220,416 shares issued    and outstanding as of  March 31, 2025 and December 31, 2024, respectively

     489,313

     484,722

     Accumulated other comprehensive loss

     (2,681
     )

     (2,876
     )

     Accumulated deficit

     (407,604
     )

     (403,465
     )

     Lineage's shareholders’ equity

     79,028

     78,381

     Noncontrolling deficit

     (1,373
     )

     (1,369
     )

     Total shareholders’ equity

     77,655

     77,012

     TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
      
     $
     111,753

     $
     113,218

See accompanying notes to the condensed consolidated interim financial statements.